Characteristics of the study (n=87) group, and main outcomes_
| Variable | Values | ||
|---|---|---|---|
| Age (years) | 48.84±7.43 | ||
| Gender (male) | 30 (34.5%) | ||
| FEV1 (%) | 74.79±15.07 | ||
| mMRC | Stage 1 | 34 (39.1%) | |
| Stage 2 | 43 (49.4%) | ||
| Stage 3 | 10 (11.5%) | ||
| HAM-D scale score before SSRIs therapy | 15.79±4.43 | Related samples Wilcoxon signed rank test p<0.001 | |
| HAM-D scale score after 8 weeks of SSRIs therapy | 10.02±3.97 | ||
| Q-LES-Q-SF score before AD | 32.43±5.51 | Related samples Wilcoxon signed rank test p<0.001 | |
| Q-LES-Q-SF score after AD | 46.65±4.79 | ||
| Difference in Q-LES-Q-SF score (after – before) | 14.20 ± 2.02 | ||
Significant predictor of difference between values of the Q-LES-Q-SF score after and before the treatment with SSRIs_
| Predictor | Adjusted R2 | F | B | t | p | 95,0% Confidence Interval for B | |
|---|---|---|---|---|---|---|---|
| Lower Bound | Upper Bound | ||||||
| FEV1 | 0.051 | 5.625 (p=0.020) | −0.034 | −2.372 | 0.020 | −0.062 | −0.005 |